Published in Mol Cancer Ther on June 01, 2002
Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A (2002) 9.60
Prevalence of quadruplexes in the human genome. Nucleic Acids Res (2005) 7.79
G-quadruplexes in promoters throughout the human genome. Nucleic Acids Res (2006) 5.84
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
DNA secondary structures: stability and function of G-quadruplex structures. Nat Rev Genet (2012) 3.15
G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. Nucleic Acids Res (2006) 3.09
Not so crystal clear: the structure of the human telomere G-quadruplex in solution differs from that present in a crystal. Nucleic Acids Res (2005) 2.57
Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. Biochimie (2008) 2.38
Regulation of the human catalytic subunit of telomerase (hTERT). Gene (2012) 1.81
Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene. J Am Chem Soc (2007) 1.53
The interaction of telomeric DNA and C-myc22 G-quadruplex with 11 natural alkaloids. Nucleic Acid Ther (2012) 1.49
Structural insights into G-quadruplexes: towards new anticancer drugs. Future Med Chem (2010) 1.44
Altered gene expression in the Werner and Bloom syndromes is associated with sequences having G-quadruplex forming potential. Nucleic Acids Res (2009) 1.44
Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. J Am Chem Soc (2009) 1.42
Genome-wide analysis reveals regulatory role of G4 DNA in gene transcription. Genome Res (2007) 1.39
Metastases suppressor NM23-H2 interaction with G-quadruplex DNA within c-MYC promoter nuclease hypersensitive element induces c-MYC expression. Nucleic Acids Res (2008) 1.34
Targeting MYC Expression through G-Quadruplexes. Genes Cancer (2010) 1.29
Evidence of genome-wide G4 DNA-mediated gene expression in human cancer cells. Nucleic Acids Res (2009) 1.28
Biophysical studies of the c-MYC NHE III1 promoter: model quadruplex interactions with a cationic porphyrin. Biophys J (2006) 1.20
Formation and properties of hairpin and tetraplex structures of guanine-rich regulatory sequences of muscle-specific genes. Nucleic Acids Res (2005) 1.20
Genome-wide analysis of a G-quadruplex-specific single-chain antibody that regulates gene expression. Nucleic Acids Res (2009) 1.15
The quadruplex r(CGG)n destabilizing cationic porphyrin TMPyP4 cooperates with hnRNPs to increase the translation efficiency of fragile X premutation mRNA. Nucleic Acids Res (2009) 1.08
Greglist: a database listing potential G-quadruplex regulated genes. Nucleic Acids Res (2007) 1.07
Nucleophosmin C-terminal leukemia-associated domain interacts with G-rich quadruplex forming DNA. J Biol Chem (2010) 1.05
Zinc-finger transcription factors are associated with guanine quadruplex motifs in human, chimpanzee, mouse and rat promoters genome-wide. Nucleic Acids Res (2011) 1.04
Evidence of the formation of G-quadruplex structures in the promoter region of the human vascular endothelial growth factor gene. Nucleic Acids Res (2010) 1.04
The DEAH-box RNA helicase RHAU binds an intramolecular RNA G-quadruplex in TERC and associates with telomerase holoenzyme. Nucleic Acids Res (2011) 1.04
Impact of alternative DNA structures on DNA damage, DNA repair, and genetic instability. DNA Repair (Amst) (2014) 1.02
Defining the mode, energetics and specificity with which a macrocyclic hexaoxazole binds to human telomeric G-quadruplex DNA. Nucleic Acids Res (2007) 1.02
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer (2005) 0.97
Retracted Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proc Natl Acad Sci U S A (2004) 0.97
Genome-wide colonization of gene regulatory elements by G4 DNA motifs. Nucleic Acids Res (2009) 0.97
Sequence- and structural-selective nucleic acid binding revealed by the melting of mixtures. Nucleic Acids Res (2006) 0.96
G-quadruplexes in viruses: function and potential therapeutic applications. Nucleic Acids Res (2014) 0.95
Structure of nucleophosmin DNA-binding domain and analysis of its complex with a G-quadruplex sequence from the c-MYC promoter. J Biol Chem (2012) 0.94
G-quadruplex conformation and dynamics are determined by loop length and sequence. Nucleic Acids Res (2014) 0.93
Use of competition dialysis in the discovery of G-quadruplex selective ligands. Methods (2007) 0.93
Targeting human telomeric G-quadruplex DNA with oxazole-containing macrocyclic compounds. Biochimie (2008) 0.91
Existence of G-quadruplex structures in promoter region of oncogenes confirmed by G-quadruplex DNA cross-linking strategy. Sci Rep (2013) 0.88
DNA and the chromosome - varied targets for chemotherapy. Cell Chromosome (2004) 0.88
DNA hairpins containing the cytidine analog pyrrolo-dC: structural, thermodynamic, and spectroscopic studies. Biophys J (2009) 0.86
Molecular modeling and biophysical analysis of the c-MYC NHE-III1 silencer element. J Mol Model (2007) 0.86
Sequence, stability, and structure of G-quadruplexes and their interactions with drugs. Curr Protoc Nucleic Acid Chem (2012) 0.85
I-motif structures formed in the human c-MYC promoter are highly dynamic--insights into sequence redundancy and I-motif stability. PLoS One (2010) 0.85
End-stacking of copper cationic porphyrins on parallel-stranded guanine quadruplexes. J Biol Inorg Chem (2007) 0.84
Pentose phosphate pathway function affects tolerance to the G-quadruplex binder TMPyP4. PLoS One (2013) 0.83
"One ring to bind them all"-part I: the efficiency of the macrocyclic scaffold for g-quadruplex DNA recognition. J Nucleic Acids (2010) 0.83
Direct evidence of mitochondrial G-quadruplex DNA by using fluorescent anti-cancer agents. Nucleic Acids Res (2015) 0.83
A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti-hepatitis C target. Sci Adv (2016) 0.83
Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression. ACS Chem Biol (2015) 0.82
Not all G-quadruplexes are created equally: an investigation of the structural polymorphism of the c-Myc G-quadruplex-forming sequence and its interaction with the porphyrin TMPyP4. Org Biomol Chem (2012) 0.82
Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene. Genes (Basel) (2016) 0.79
G-quadruplexes as novel cis-elements controlling transcription during embryonic development. Nucleic Acids Res (2016) 0.79
An in silico study of the differential effect of oxidation on two biologically relevant G-quadruplexes: possible implications in oncogene expression. PLoS One (2012) 0.79
The biological activity of G-quadruplex DNA binding papaverine-derived ligand in breast cancer cells. Invest New Drugs (2008) 0.77
Mass spectrometric studies on effects of counter ions of TMPyP4 on binding to human telomeric DNA and RNA G-quadruplexes. Anal Bioanal Chem (2014) 0.77
An RNA-binding Protein, Lin28, Recognizes and Remodels G-quartets in the MicroRNAs (miRNAs) and mRNAs It Regulates. J Biol Chem (2015) 0.77
Effects of Replication and Transcription on DNA Structure-Related Genetic Instability. Genes (Basel) (2017) 0.76
TMPyP4, a Stabilizer of Nucleic Acid Secondary Structure, Is a Novel Acetylcholinesterase Inhibitor. PLoS One (2015) 0.76
Telomerase as a Cancer Target. Development of New Molecules. Curr Top Med Chem (2016) 0.76
Wild-type p53 binds to MYC promoter G-quadruplex. Biosci Rep (2016) 0.76
Possible regulatory roles of promoter g-quadruplexes in cardiac function-related genes - human TnIc as a model. PLoS One (2013) 0.76
Suppression of STN1 enhances the cytotoxicity of chemotherapeutic agents in cancer cells by elevating DNA damage. Oncol Lett (2016) 0.76
Control of bacterial nitrate assimilation by stabilization of G-quadruplex DNA. Chem Commun (Camb) (2016) 0.75
A water soluble tri-cationic porphyrin-EDTA conjugate induces apoptosis in human neuroendocrine tumor cell lines. Bioorg Chem (2011) 0.75
Ruthenation of Non-stacked Guanines in DNA G-Quadruplex Structures: Enhancement of c-MYC Expression. Angew Chem Int Ed Engl (2016) 0.75
TMPyP4 promotes cancer cell migration at low doses, but induces cell death at high doses. Sci Rep (2016) 0.75
Keeping those telomeres short! an innovative intratumoral long-term drug delivery system. J Cancer Res Clin Oncol (2014) 0.75
Influence of H2TOEtPyP4 porphyrin on the stability and conductivity of bilayer lipid membranes. Eur Biophys J (2015) 0.75
Telomeres and telomerase in prostate cancer development and therapy. Nat Rev Urol (2017) 0.75
RNA G-quadruplexes in biology: Principles and molecular mechanisms. J Mol Biol (2017) 0.75
Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A (2002) 9.60
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61
Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov (2011) 3.54
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. J Am Chem Soc (2004) 3.19
Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res (2005) 3.01
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53
Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. Biochimie (2008) 2.38
Evidence for the presence of a guanine quadruplex forming region within a polypurine tract of the hypoxia inducible factor 1alpha promoter. Biochemistry (2005) 2.27
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
NMR solution structure of the major G-quadruplex structure formed in the human BCL2 promoter region. Nucleic Acids Res (2006) 2.03
The importance of negative superhelicity in inducing the formation of G-quadruplex and i-motif structures in the c-Myc promoter: implications for drug targeting and control of gene expression. J Med Chem (2009) 2.03
Antitumor activity of a kinesin inhibitor. Cancer Res (2004) 1.93
Deconvoluting the structural and drug-recognition complexity of the G-quadruplex-forming region upstream of the bcl-2 P1 promoter. J Am Chem Soc (2006) 1.93
Targeting Axl and Mer kinases in cancer. Mol Cancer Ther (2011) 1.88
Telomestatin and diseleno sapphyrin bind selectively to two different forms of the human telomeric G-quadruplex structure. J Am Chem Soc (2005) 1.87
Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets (2004) 1.86
Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc (2002) 1.82
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75
The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat Rev Cancer (2009) 1.71
PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther (2005) 1.67
Characterization of the G-quadruplexes in the duplex nuclease hypersensitive element of the PDGF-A promoter and modulation of PDGF-A promoter activity by TMPyP4. Nucleic Acids Res (2007) 1.66
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 1.65
Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer (2011) 1.64
Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov (2006) 1.60
Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene. J Am Chem Soc (2007) 1.53
RuleMonkey: software for stochastic simulation of rule-based models. BMC Bioinformatics (2010) 1.49
A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity. Nucleic Acids Res (2008) 1.49
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med (2009) 1.48
The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents. Mol Cancer Ther (2008) 1.44
Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. J Am Chem Soc (2009) 1.42
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J Am Chem Soc (2005) 1.40
Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. Semin Oncol (2006) 1.39
Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res (2012) 1.33
The c-MYC NHE III(1): function and regulation. Annu Rev Pharmacol Toxicol (2010) 1.31
Targeting MYC Expression through G-Quadruplexes. Genes Cancer (2010) 1.29
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res (2009) 1.29
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther (2003) 1.26
The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res (2003) 1.25
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther (2004) 1.24
Targeting Aurora-2 kinase in cancer. Mol Cancer Ther (2003) 1.23
Enhanced targeting with heterobivalent ligands. Mol Cancer Ther (2009) 1.21
Structure of the biologically relevant G-quadruplex in the c-MYC promoter. Nucleosides Nucleotides Nucleic Acids (2006) 1.21
Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res (2004) 1.21
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
Biophysical studies of the c-MYC NHE III1 promoter: model quadruplex interactions with a cationic porphyrin. Biophys J (2006) 1.20
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther (2010) 1.20
NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III(1). Mol Cancer Ther (2009) 1.19
Simulation of large-scale rule-based models. Bioinformatics (2009) 1.18
Solution structure of a 2:1 quindoline-c-MYC G-quadruplex: insights into G-quadruplex-interactive small molecule drug design. J Am Chem Soc (2011) 1.17
Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov (2011) 1.17
Telomere inhibition and telomere disruption as processes for drug targeting. Annu Rev Pharmacol Toxicol (2002) 1.17
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res (2011) 1.17
Biochemical techniques for the characterization of G-quadruplex structures: EMSA, DMS footprinting, and DNA polymerase stop assay. Methods Mol Biol (2010) 1.16
Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene. Nucleic Acids Res (2008) 1.16
Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem (2011) 1.14
Telomeres and telomerases as drug targets. Curr Opin Pharmacol (2002) 1.14
Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. BMC Genomics (2013) 1.13
Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol (2006) 1.12
Dietary administration of the proapoptotic vitamin E analogue alpha-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Res (2006) 1.11
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10
The cationic porphyrin TMPyP4 destabilizes the tetraplex form of the fragile X syndrome expanded sequence d(CGG)n. Nucleic Acids Res (2003) 1.09
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat (2014) 1.08
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res (2002) 1.07
The C-terminus of nucleolin promotes the formation of the c-MYC G-quadruplex and inhibits c-MYC promoter activity. Biochemistry (2010) 1.07
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res (2006) 1.06
The dynamic character of the BCL2 promoter i-motif provides a mechanism for modulation of gene expression by compounds that bind selectively to the alternative DNA hairpin structure. J Am Chem Soc (2014) 1.06
Molecular cloning of the human platelet-derived growth factor receptor beta (PDGFR-beta) promoter and drug targeting of the G-quadruplex-forming region to repress PDGFR-beta expression. Biochemistry (2010) 1.06
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res (2006) 1.06
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol (2008) 1.05
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther (2012) 1.05
The i-motif in the bcl-2 P1 promoter forms an unexpectedly stable structure with a unique 8:5:7 loop folding pattern. J Am Chem Soc (2009) 1.04
Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale J Biol Med (2009) 1.03